Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Ewing sarcoma, drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Metastatic-to-bone and relapsed disease: survival under 20-30%.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
EWSR1-FLI1 remains undrugged after 30 years.
Background: p53 / RB / cell-cycle checkpoint. Also on OnCo: Targets · KRAS roadmap.
Late effects: cardiotoxicity, infertility, secondary leukaemia (etoposide, alkylators), radiation-induced sarcoma.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Ancestry-linked incidence differences (GGAA microsatellite polymorphism) unexplained.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Cabozantinib met the activity thresholds in both the Ewing sarcoma and osteosarcoma cohorts.
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.
A milestone in how this cancer is treated.